IL266470A - Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitors - Google Patents
Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitorsInfo
- Publication number
- IL266470A IL266470A IL266470A IL26647019A IL266470A IL 266470 A IL266470 A IL 266470A IL 266470 A IL266470 A IL 266470A IL 26647019 A IL26647019 A IL 26647019A IL 266470 A IL266470 A IL 266470A
- Authority
- IL
- Israel
- Prior art keywords
- azetidine
- cyclobutane
- alpha
- containing mono
- integrin inhibitors
- Prior art date
Links
- PJECMAFJDCWMIR-UHFFFAOYSA-N azetidine cyclobutane Chemical compound N1CCC1.C1CCC1 PJECMAFJDCWMIR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418859P | 2016-11-08 | 2016-11-08 | |
| PCT/US2017/060383 WO2018089355A1 (en) | 2016-11-08 | 2017-11-07 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL266470A true IL266470A (en) | 2019-07-31 |
Family
ID=60409434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266470A IL266470A (en) | 2016-11-08 | 2019-05-06 | Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11014922B2 (https=) |
| EP (1) | EP3538526B1 (https=) |
| JP (1) | JP7264810B2 (https=) |
| KR (1) | KR102506324B1 (https=) |
| CN (1) | CN110167934B (https=) |
| AR (1) | AR110139A1 (https=) |
| AU (1) | AU2017359025A1 (https=) |
| BR (1) | BR112019009129A2 (https=) |
| CA (1) | CA3042710A1 (https=) |
| EA (1) | EA201991127A1 (https=) |
| ES (1) | ES2984394T3 (https=) |
| IL (1) | IL266470A (https=) |
| MA (1) | MA46744A (https=) |
| MX (1) | MX377359B (https=) |
| TW (1) | TW201819378A (https=) |
| WO (1) | WO2018089355A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| US11306084B2 (en) | 2016-12-29 | 2022-04-19 | Saint Louis University | Integrin antagonists |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| TWI841573B (zh) * | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| CN113354635B (zh) * | 2020-03-06 | 2023-04-18 | 清药同创(北京)药物研发中心有限公司 | 一种吡咯烷类整合素调节剂及其用途 |
| WO2021191391A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| TW202216715A (zh) | 2020-07-07 | 2022-05-01 | 大陸商四川海思科製藥有限公司 | 降解btk激酶的化合物、製造方法及其應用 |
| GB202010626D0 (en) * | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2022022364A1 (zh) * | 2020-07-29 | 2022-02-03 | 清药同创(北京)药物研发中心有限公司 | 一种吡咯烷类整合素调节剂及其用途 |
| KR20230169979A (ko) * | 2021-03-10 | 2023-12-18 | 다이스 몰레큘스 에스브이, 인크. | 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도 |
| MX2023012794A (es) * | 2021-04-30 | 2023-12-15 | Pliant Therapeutics Inc | Regímenes de dosificación expandidos para inhibidores de integrina. |
| TW202321219A (zh) | 2021-08-11 | 2023-06-01 | 大陸商四川海思科製藥有限公司 | 雜環衍生物及其組合物和藥學上的應用 |
| EP4504188A4 (en) * | 2022-04-01 | 2026-04-08 | Praxis Prec Medicines Inc | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIROHEPTANE CORE AND THEIR METHODS OF USE |
| AU2023245572A1 (en) * | 2022-04-01 | 2024-10-17 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof |
| GB202301024D0 (en) | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| CN117003681A (zh) * | 2023-07-04 | 2023-11-07 | 苏州汉德创宏生化科技有限公司 | 一种抑制剂类中间体及其合成方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| ZA972195B (en) * | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| CA2309204A1 (en) * | 1997-11-26 | 1999-06-03 | Dupont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists |
| CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| AU748621B2 (en) | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
| CN1589145A (zh) * | 1999-06-02 | 2005-03-02 | 麦克公司 | αv整联蛋白受体拮抗剂 |
| CA2436130A1 (en) | 2001-01-29 | 2002-08-08 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted indoles and their use as integrin antagonists |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016145258A1 (en) * | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| US10526287B2 (en) * | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| HRP20210228T1 (hr) * | 2016-11-08 | 2021-03-19 | Bristol-Myers Squibb Company | Amidi pirola kao inhibitori alfa v integrina |
| AU2017359023B2 (en) * | 2016-11-08 | 2021-12-09 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
-
2017
- 2017-11-07 ES ES17801232T patent/ES2984394T3/es active Active
- 2017-11-07 EP EP17801232.4A patent/EP3538526B1/en active Active
- 2017-11-07 CA CA3042710A patent/CA3042710A1/en not_active Abandoned
- 2017-11-07 CN CN201780082145.2A patent/CN110167934B/zh active Active
- 2017-11-07 MX MX2019005306A patent/MX377359B/es active IP Right Grant
- 2017-11-07 AR ARP170103089A patent/AR110139A1/es unknown
- 2017-11-07 TW TW106138359A patent/TW201819378A/zh unknown
- 2017-11-07 WO PCT/US2017/060383 patent/WO2018089355A1/en not_active Ceased
- 2017-11-07 KR KR1020197016079A patent/KR102506324B1/ko active Active
- 2017-11-07 EA EA201991127A patent/EA201991127A1/ru unknown
- 2017-11-07 AU AU2017359025A patent/AU2017359025A1/en not_active Abandoned
- 2017-11-07 US US16/347,849 patent/US11014922B2/en active Active
- 2017-11-07 JP JP2019523859A patent/JP7264810B2/ja active Active
- 2017-11-07 MA MA046744A patent/MA46744A/fr unknown
- 2017-11-07 BR BR112019009129A patent/BR112019009129A2/pt not_active Application Discontinuation
-
2019
- 2019-05-06 IL IL266470A patent/IL266470A/en unknown
-
2021
- 2021-03-25 US US17/212,210 patent/US11639353B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7264810B2 (ja) | 2023-04-25 |
| CA3042710A1 (en) | 2018-05-17 |
| MA46744A (fr) | 2019-09-18 |
| BR112019009129A2 (pt) | 2019-07-16 |
| AR110139A1 (es) | 2019-02-27 |
| ES2984394T3 (es) | 2024-10-29 |
| US11639353B2 (en) | 2023-05-02 |
| MX2019005306A (es) | 2019-08-12 |
| CN110167934B (zh) | 2022-06-10 |
| US11014922B2 (en) | 2021-05-25 |
| AU2017359025A1 (en) | 2019-06-20 |
| TW201819378A (zh) | 2018-06-01 |
| KR102506324B1 (ko) | 2023-03-03 |
| EP3538526A1 (en) | 2019-09-18 |
| EA201991127A1 (ru) | 2019-10-31 |
| KR20190076032A (ko) | 2019-07-01 |
| US20210246136A1 (en) | 2021-08-12 |
| EP3538526B1 (en) | 2024-04-10 |
| MX377359B (es) | 2025-03-10 |
| JP2019537605A (ja) | 2019-12-26 |
| US20190270741A1 (en) | 2019-09-05 |
| CN110167934A (zh) | 2019-08-23 |
| WO2018089355A1 (en) | 2018-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266470A (en) | Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitors | |
| IL321844A (en) | Menin–MLL interaction inhibitors | |
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| PL3512850T3 (pl) | Inhibitory interakcji menina-mll | |
| ZA201707912B (en) | Tetrasubstituted alkene compounds and their use | |
| IL248158B (en) | Conjugated bicyclic substances containing aryl or heteroaryl errors and their use as irak4 inhibitors | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| EP3110820A4 (en) | Tyk2 inhibitors and uses thereof | |
| SG11201609248WA (en) | Nox inhibitor and nfκb inhibitor containing methoxyflavone | |
| SG11201708027XA (en) | Compounds and their use as bace1 inhibitors | |
| SG11201708820TA (en) | Ebna1 inhibitors and methods using same | |
| IL254916B (en) | Inhibitors and their uses | |
| IL258328B (en) | A bicyclic compound and its use to inhibit suv39h2 | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| IL258222A (en) | Compositions and methods for inhibiting beta-lactamase | |
| EP3089675A4 (en) | Devices and methods for advancing knots | |
| GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| HK1248143A1 (en) | Tetrasubstituted alkene compounds and their use | |
| GB201409466D0 (en) | Urea compounds and their use as enzyme inhibitors |